Gene: B4GALNT1
Official Full Name: beta-1,4-N-acetyl-galactosaminyltransferase 1provided by HGNC
Gene Summary: GM2 and GD2 gangliosides are sialic acid-containing glycosphingolipids. GalNAc-T is the enzyme involved in the biosynthesis of G(M2) and G(D2) glycosphingolipids. GalNAc-T catalyzes the transfer of GalNAc into G(M3) and G(D3) by a beta-1,4 linkage, resulting in the synthesis of G(M2) and G(D2), respectively. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2013]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO37749 | B4GALNT1 Knockout cell line (HeLa) | Human | B4GALNT1 | 1:3~1:6 | Negative | Online Inquiry |
KO37750 | B4GALNT1 Knockout cell line (HCT 116) | Human | B4GALNT1 | 1:2~1:4 | Negative | Online Inquiry |
KO37751 | B4GALNT1 Knockout cell line (HEK293) | Human | B4GALNT1 | 1:3~1:6 | Negative | Online Inquiry |
KO37752 | B4GALNT1 Knockout cell line (A549) | Human | B4GALNT1 | 1:3~1:4 | Negative | Online Inquiry |
B4GALNT1 Gene Knockout Cell Lines are engineered biological tools that facilitate the study of the B4GALNT1 gene, responsible for encoding the enzyme β-1,4-N-acetylgalactosaminyltransferase 1. These specifically designed cell lines utilize CRISPR-Cas9 technology to achieve complete knockout of the B4GALNT1 gene, providing researchers a powerful model to elucidate the gene's role in glycosylation processes and related cellular pathways.
The primary function of these knockout cell lines is to observe the phenotypic and molecular consequences of the loss of B4GALNT1 expression. By examining alterations in glycan structures on cell surfaces, researchers can gain insights into how changes in glycosylation may impact cell adhesion, signaling, and overall cellular behavior. This understanding can lead to advancements in the knowledge of various diseases, including cancer and neurological disorders, where glycosylation processes are often disrupted.
In scientific research and clinical applications, B4GALNT1 Gene Knockout Cell Lines are invaluable for drug development, biomarker discovery, and the study of disease mechanisms. These cell lines allow for cost-effective, reproducible experiments that pave the way for targeted therapeutic strategies and personalized medicine approaches, enhancing the translational potential of research findings.
Compared to traditional knockout methods, our B4GALNT1 Gene Knockout Cell Lines offer superior specificity and efficiency, minimizing off-target effects and ensuring reliable gene disruption. Their ready-to-use nature provides convenience and saves valuable laboratory time, allowing researchers to focus on their core hypothesis rather than cell line development.
Investing in B4GALNT1 Gene Knockout Cell Lines is a strategic choice for researchers and clinicians dedicated to advancing their understanding of glycosylation and its implications in health and disease. Our company prides itself on delivering high-quality, reliable biological products, backed by expertise in genetic engineering and cell biology that ensures our customers receive the best tools to propel their research forward.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.